Labcorp Adds High Sensitivity Antigen Test to Screen for Active COVID-19 Infection
February 17 2021 - 6:57AM
Business Wire
Antigen Test Is the Latest Offering by Labcorp
to Fight COVID-19 at Every Stage, from Diagnostic Testing to
Clinical Trials and Vaccination Services
Labcorp (NYSE: LH), a leading global life sciences company,
today announced the availability of a new laboratory-based antigen
test that will help doctors determine if an individual is actively
infected with COVID-19.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210217005506/en/
Photo courtesy of Labcorp (Photo:
Business Wire)
Developed by DiaSorin, the antigen test is available to patients
through a doctor’s order and allows for testing to determine if
individuals are still infected with and could spread COVID-19. The
test is performed by a doctor or other healthcare provider using a
nasal or nasopharyngeal swab to collect a sample and is then picked
up and processed by Labcorp. Results are available on average
within 24-48 hours from time of pick up.
“This new high-sensitivity antigen test is another example of
Labcorp’s commitment to providing people with the information they
need to make important health decisions,” said Dr. Brian Caveney,
chief medical officer and president, Labcorp Diagnostics. “PCR
tests are still considered the gold standard in diagnosing
COVID-19, as they are able to detect the smallest traces of the
virus. However, an antigen test is an additional tool to help
individuals know if they could still be carrying the virus or if
they are safe to resume work and life activities.”
According to the Centers for Disease Control and Prevention
(CDC), antigen tests can be used in a variety of testing strategies
to respond to the COVID-19 pandemic and are helpful in determining
whether a person diagnosed with COVID-19 remains infectious.
Labcorp continues to recommend that individuals follow health
guidelines, including wearing a mask in public, socially
distancing, frequently washing hands and avoiding large groups, and
receiving a COVID-19 vaccine as availability increases and the CDC
guidance expands to more eligible groups. For more information
about Labcorp’s COVID-19 response and testing options, visit
Labcorp’s COVID-19 microsite.
The DiaSorin LIAISON® SARS-CoV-2 Ag antigen test has been made
available to the U.S. market following notification to the U.S.
Food and Drug Administration (FDA) on October 26, 2020 pursuant to
the FDA’s Policy for Diagnostic Tests for Coronavirus Disease-2019
during the Public Health Emergency (Revised) and published May 11,
2020.
About Labcorp
Labcorp is a leading global life sciences company that provides
vital information to help doctors, hospitals, pharmaceutical
companies, researchers, and patients make clear and confident
decisions. Through our unparalleled diagnostics and drug
development capabilities, we provide insights and accelerate
innovations to improve health and improve lives. With over 75,000
employees, we serve clients in more than 100 countries. Labcorp
(NYSE: LH) reported revenue of $14 billion in FY2020. Learn about
Labcorp at www.Labcorp.com, or follow us on LinkedIn and Twitter
@Labcorp.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements,
including but not limited to statements with respect to clinical
laboratory testing and the potential benefits of a COVID-19 test
home collection kit and our responses to and the expected future
impacts of the COVID-19 pandemic and the opportunities for future
growth. Each of the forward-looking statements is subject to change
based on various important factors, many of which are beyond the
Company’s control, including without limitation, whether our
response to the COVID-19 pandemic will prove effective, the impact
of the COVID-19 pandemic on our business and financial condition,
as well as on general economic, business, and market conditions,
competitive actions and other unforeseen changes and general
uncertainties in the marketplace, changes in government
regulations, including healthcare reform, customer purchasing
decisions, including changes in payer regulations or policies,
other adverse actions of governmental and third-party payers, the
Company’s satisfaction of regulatory and other requirements,
patient safety issues, changes in testing guidelines or
recommendations, federal, state, and local governmental responses
to the COVID-19 pandemic, adverse results in material litigation
matters, failure to maintain or develop customer relationships, our
ability to develop or acquire new products and adapt to
technological changes, failure in information technology, systems
or data security, and employee relations. These factors, in some
cases, have affected and in the future (together with other
factors) could affect the Company’s ability to implement the
Company’s business strategy and actual results could differ
materially from those suggested by these forward-looking
statements. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements. The Company has
no obligation to provide any updates to these forward-looking
statements even if its expectations change. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. Further information on potential factors,
risks and uncertainties that could affect operating and financial
results is included in the Company’s most recent Annual Report on
Form 10-K and subsequent Forms 10-Q, including in each case under
the heading RISK FACTORS, and in the Company’s other filings with
the SEC.
# # #
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210217005506/en/
Labcorp Contacts: Media: Christopher Allman-Bradshaw —
336-436-8263 Media@Labcorp.com
Investors: Chas Cook —
336-436-5076 Investor@Labcorp.com
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024